LBPH vs. SAGE, PLRX, YMAB, TNGX, EOLS, SIGA, ARCT, COGT, PRTC, and AUPH
Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Sage Therapeutics (SAGE), Pliant Therapeutics (PLRX), Y-mAbs Therapeutics (YMAB), Tango Therapeutics (TNGX), Evolus (EOLS), SIGA Technologies (SIGA), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), PureTech Health (PRTC), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
Longboard Pharmaceuticals (NASDAQ:LBPH) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
Longboard Pharmaceuticals presently has a consensus target price of $43.67, suggesting a potential upside of 117.03%. Sage Therapeutics has a consensus target price of $37.67, suggesting a potential upside of 216.53%. Given Sage Therapeutics' higher probable upside, analysts clearly believe Sage Therapeutics is more favorable than Longboard Pharmaceuticals.
In the previous week, Longboard Pharmaceuticals had 12 more articles in the media than Sage Therapeutics. MarketBeat recorded 17 mentions for Longboard Pharmaceuticals and 5 mentions for Sage Therapeutics. Longboard Pharmaceuticals' average media sentiment score of 0.15 beat Sage Therapeutics' score of 0.14 indicating that Longboard Pharmaceuticals is being referred to more favorably in the media.
Longboard Pharmaceuticals has higher earnings, but lower revenue than Sage Therapeutics. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
Longboard Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Longboard Pharmaceuticals has a net margin of 0.00% compared to Sage Therapeutics' net margin of -552.52%. Longboard Pharmaceuticals' return on equity of -49.87% beat Sage Therapeutics' return on equity.
63.3% of Longboard Pharmaceuticals shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 4.6% of Longboard Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Sage Therapeutics received 582 more outperform votes than Longboard Pharmaceuticals when rated by MarketBeat users. However, 73.33% of users gave Longboard Pharmaceuticals an outperform vote while only 67.82% of users gave Sage Therapeutics an outperform vote.
Summary
Longboard Pharmaceuticals beats Sage Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Longboard Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longboard Pharmaceuticals Competitors List
Related Companies and Tools
